CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗复发/难治性 B 细胞急性淋巴细胞白血病疗效的荟萃分析
英文原题：A Meta-analysis on Effects of Chimeric Antigen Receptor T-cell Therapy in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
查看英文原题
A Meta-analysis on Effects of Chimeric Antigen Receptor T-cell Therapy in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
CAR-T 细胞疗法是治疗 r/r B-ALL 的一项突破性进展，可实现高比例的持久缓解。
研究思路结论见上方概要
目的
本综述评估了嵌合抗原受体（CAR）T细胞疗法在复发/难治性B细胞急性淋巴细胞白血病（r/r B-ALL）患者中的长期结局和不良事件。
方法
我们在相关数据库中进行了检索，截止至2024年6月。我们纳入了针对r/r B-ALL患者CAR-T 细胞治疗的临床试验。使用Comprehensive Meta-Analysis V3和Review Manager 5.4进行Meta分析。
结果
在2659项已识别的研究中，10项被纳入本综述。汇总分析显示，微小残留病阴性完全缓解率较高，总体事件率（ER）为70%（95% CI：61%-78%，I2=88.35%）。抗CD19 CAR-T 细胞疗法显示出最高疗效，ER为74.75%（95% CI：61%-80%，I2=89.84%）。靶向CD19和CD22的联合治疗ER为69%（95% CI：53%-83%，I2=82.56%）。显著的不良反应包括细胞因子释放综合征，平均发生率为81.8%（95% CI：76.7%-86.9%），神经毒性为33.2%（95% CI：28.1%-38.3%），血液学毒性为71.9%（95% CI：66.4%-77.4%）。
展开英文摘要原文
OBJECTIVES
This review evaluates the long-term outcomes and adverse events associated with chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
METHODS
We conducted the search in relevant databases up to June 2024. We included clinical trials on CAR T-cell therapy for patients with r/r B-ALL. Meta-analyses were conducted using Comprehensive Meta-Analysis V3 and Review Manager 5.4.
RESULTS
Out of 2659 identified studies, 10 were included in this review. The pooled analysis demonstrated a high minimal residual disease-negative complete remission, with an overall event rate (ER) of 70% (95% CI: 61%-78%, I2 =8 8.35%). Anti-CD19 CAR T-cell therapy showed the highest efficacy with an ER of 74.75% (95% CI: 61%-80%, I2 = 89.84%). Combination therapies targeting CD19 and CD22 had an ER of 69% (95% CI: 53%-83%, I2 = 82.56%). Significant adverse effects included cytokine release syndrome with a mean incidence of 81.8% (95% CI: 76.7%-86.9%), neurotoxicity at 33.2% (95% CI: 28.1%-38.3%), and hematologic toxicities at 71.9% (95% CI: 66.4%-77.4%).
CONCLUSIONS
CAR T-cell therapy is a groundbreaking advancement in treating r/r B-ALL, offering high rates of durable remissions.
论文信息
- 作者
- Jamil A、Qureshi Z、Siddique R、Altaf F、Jamil R、Wali N
- 第一作者单位
- Department of Medicine, Samaritan Medical Centre.
- 通讯作者单位
- Vituity Hospitalist Group, HSHS St. John's Hospital Springfield, IL.
- 文献类型
- 荟萃分析
- 期刊
- American journal of clinical oncology2025 Jun 1
- 原文标识
- PubMed 39956997 · DOI 10.1097/COC.0000000000001176